Register Login

Keros Therapeutics Inc (KROS)

  • Event
  • Aug. 04, 2022, 21:13 UTC

(10% Negative) Keros Therapeutics, Inc. (KROS) Announces Delay in trials Trials for KER-050 Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 7:16 p.m.

    📋 Keros Therapeutics, Inc. (KROS) - Clinical Trial Update

    Filing Date: 2022-08-04

    Accepted: 2022-08-04 17:13:45

    Event Type: Clinical Trial Update

    Event Details:

    Keros Therapeutics Inc (KROS) Announces Clinical Trial Update Keros Therapeutics Inc (KROS) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: trials, contained
    • Diseases/Conditions: KER-050
    • Clinical Stage: clinical trial
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: COVID-19 on Keros

    🔬 Clinical Development Pipeline (Keros Therapeutics, Inc.):

    Product Type Development Stage Therapeutic Area Source
    VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection) BIOLOGICAL Phase PHASE1 Head and Neck Cancers- Squamous Cell ClinicalTrials.gov
    Pembrolizumab (KEYTRUDA®) DRUG Phase PHASE1 Head and Neck Cancers- Squamous Cell ClinicalTrials.gov
    VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection) BIOLOGICAL Phase PHASE1 Head and Neck Cancers- Squamous Cell ClinicalTrials.gov
    Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks BIOLOGICAL Phase PHASE2 Pulmonary Arterial Hypertension ClinicalTrials.gov
    Dose C KER-012 BIOLOGICAL Phase PHASE2 Pulmonary Arterial Hypertension ClinicalTrials.gov
    Dose B KER-012 BIOLOGICAL Phase PHASE2 Pulmonary Arterial Hypertension ClinicalTrials.gov
    Dose A KER-012 BIOLOGICAL Phase PHASE2 Pulmonary Arterial Hypertension ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Keros Therapeutics Inc
    • CIK: 0001664710
    • Ticker Symbol: KROS
    • Period End Date: 2022-08-04
    • Document Type: 8-K

Search

News categories